FDA approves clinical application of Ignyta immunomodulator RXDX-106 for solid tumors
January 02, 2018 Source: Sina Pharmaceutical
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];On December 29th, Ignyta, a tumor-accurate medical biotechnology company that was acquired by Roche for $1.7 billion, publicly stated that the US FDA approved the company's drug candidate RXDX-106 for clinical trials (IND) for solid tumor therapy, which is TAM ( TYRO3, AXL, MER) inhibitor is a new oral immunomodulator drug.
Following the approval of this IND application, Ignyta will proceed with the TITAN (Targeted Immunomodulatory TAM Antagonist) study of RXDX-106 in patients with locally advanced or metastatic solid tumors, which is a multicenter open-label dose escalation trial. It is the first test conducted in the crowd. The TITAN trial will primarily assess the safety, tolerability, pharmacokinetics, and initial effectiveness of RXDX-106.
Dr. Jonathan Lim, CEO of Ignyta, said: “RXDX-106 is the representative of new cancer immunotherapy drugs, and we are very excited about the approval of clinical trials. RXDX-106 has been proven through previous preclinical studies. Targeting the tumor microenvironment, the TAM receptor family, whether monotherapy or combined with immunological checkpoint inhibitors, can stimulate and enhance the potential for immune responses to cancer. This drug candidate further enhances our commitment to The mission of developing new drugs for cancer patients. The clinical phase 1 trial will begin in early 2018."
RXDX-106 is a novel oral immunomodulator with potent non-clinical anti-tumor activity that reverses tumor microenvironment (TME) by inhibiting TYRO3, AXL and MER receptor tyrosine kinases (collectively TAM) Immunosuppression of innate immune cells to restore and enhance the immune function of the entire body. In the tumor microenvironment, the receptor tyrosine kinase TAM contributes to the escape of immune cells and tumor progression by promoting the anti-inflammatory and tumorigenic activity of tumor cells. As a potent and selective TAM inhibitor, RXDX-106 has the potential to reverse TAM-mediated immunosuppression and inhibit tumor growth and progression.
Based in San Diego, California, Ignyta is a precision medical company that provides integrated RX/DX (precise targeted therapy/diagnosis) solutions for the treatment of cancer and immune diseases. The goal is to discover and develop activated genes in cancer cells. A revolutionary new drug that targets or reactivates the immune system for personalized treatment of cancer patients. On December 23, 2017, Roche Pharmaceuticals announced an acquisition agreement with Ignyta for US$1.7 billion, and obtained the latter's new anti-cancer drug entrectinib. (Sina Pharmaceutical Compilation / David)
Article Reference Source: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
We have Natural Plant Intermediates,Organic Flax Seed,Organic Apricot Kernel, Organic Pine Nut,Acacetin Supplement ,Piperine Blood Pressure , Herbal extract - Plant Extract : Organic Extract ; Fruit & vegetable powder ; plant Essential Oil
Xi'an Henrikang Biotech Co., Ltd., has a high-quality talent team and well-equipped quality control laboratory. In the Skin Whitening production enterprises far ahead of other enterprises. Sweeteners we are also a high-quality supplier, absolutely reliable quality, absolutely competitive price. The factory has a RESEARCH and development and quality testing center, with strong technical research and development strength. Preservatives also has 3 sales departments, more than 30 people, and our products are sold all over the world.Nutrition Supplements sales in foreign countries our company has a long-term stable market and partners in Sex Enhancement Powder, We are very professional suppliers, looking forward to cooperating with you, welcome to consult us.
Natural plant intermediates,Organic Flax Seed,Organic Apricot Kernel, Organic Pine Nut,Acacetin Supplement,Piperine Blood Pressure
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com